Evidence map›Paper›PMID 29293580›Full record

ArticlePloS one2018

Clinical response of tuberculosis patients, a prospective cohort study.

Berhanu Elfu Feleke, Getu Degu Alene, Teferi Elfu Feleke, Yalmezerf Motebaynore, Fantahun Biadglegne

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Therapeutic drug monitoring in tuberculosis.European journal of clinical pharmacology · 2024
    Review
  3. Treatment Response in Pediatric Pulmonary Tuberculosis-A Prospective Longitudinal Study.Journal of the Pediatric Infectious Diseases Society · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Berhanu Elfu FelekeDepartment of Epidemiology and Biostatistics, University of Bahir Dar, Bahir Dar, Ethiopian.ORCID 0000-0001-9251-3337
Getu Degu AleneDepartment of Epidemiology and Biostatistics, University of Bahir Dar, Bahir Dar, Ethiopian.
Teferi Elfu FelekeDepartment of Pediatrics, University of St. Paul, Addis Ababa, Ethiopian.
Yalmezerf MotebaynoreDepartment of Internal Medicine, University of Bahir Dar, Bahir Dar, Ethiopian.
Fantahun BiadglegneDepartment of Microbiology, University of Bahir Dar, Bahir Dar, Ethiopian.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical response means a response to drug intake that can be detected and appreciated by a change in signs and symptoms. The objectives of this study were to assess time to clinical response, the incidence density for clinical response and determinants of clinical response of tuberculosis (TB) patients in the intensive phases of TB treatment. Prospective cohort study design was implemented. The target population for this study was all patients following the directly observed therapy. Baseline data has been collected during the start of the directly observed TB treatment strategy. We have been collected updated data after the seven days of the baseline data collection, then after every seven days updated data has been collected from each pulmonary and extra pulmonary TB patients. Kaplan Meier curve was used to estimate time to clinical response. Incidence density using person days was used to estimate incidence of clinical response. Cox proportional hazard model was used to identify the predictors of clinical responses. A total of 1608 TB patients were included with a response rate at 99.5%. The mean age of the respondents was 24.5 years [standard deviation (SD) 14.34 years]. The incidence density for clinical response was 1429/38529 person days. One fourth of the TB patients showed clinical response at day 14, 25% of at day 21 and 75% o at day 31. Predictors of clinical response for TB patients includes: age (AHR 1.007 [95% CI 1.003-1.011]), type of TB (AOR 2.3[95% CI 2.04-2.59]), Previous history of TB (AHR 0.18 [95% CI 0.11-0 .30]), Intestinal parasitic infection (AOR 0.22[95% CI 0.19-0.26]), hemoglobin (AOR 2.35 [95% CI 2.18-2.54]), weight gain (AOR 1.11 [95% CI 1.05-1.17]), Micronutrient supplementation (AOR 9.71 [95% CI 8.28-11.38]), male sex (AOR 0.87 [95% CI 0.79-0.97]).The clinical responses for extra-pulmonary TB patients were slower than pulmonary TB. Deworming and micronutrient supplementation should be considered as the additional TB treatment strategy for TB patients.

Indexed as

AdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleMiddle AgedProportional Hazards ModelsProspective StudiesTuberculosisYoung Adult

Identifiers

PMID29293580
PMCPMC5749762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.